| 03.07 08:15 | dpa-AFX: Sanofi-Blockbuster Dupixent: Zulassung in Europa für spezielle Lungenkrankheit |
| 03.07 08:15 | Sanofi-Blockbuster Dupixent: Zulassung in Europa für spezielle Lungenkrankheit |
| 03.07 08:10 | dpa-AFX: Sanofi-Blockbuster Dupixent: Zulassung in Europa für spezielle Lungenkrankheit |
| 03.07 07:39 | Sanofi erhält EU-Zulassung für Dupixent als COPD-Therapie |
| 03.07 07:31 | dpa-AFX: Regeneron, Sanofi: EU Approves Dupixent As First-ever Targeted Therapy For COPD Patients |
| 03.07 07:11 | dpa-AFX: *REGENERON: EC APPROVES DUPIXENT AS ADD-ON MAINTENANCE TREATMENT FOR ADULTS WITH COPD |
| 28.06 13:20 | dpa-AFX: Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU |
| 28.06 13:11 | dpa-AFX: *REGENERON: ODRONEXTAMAB RECOMMENDED FOR EU APPROVAL BY CHMP TO TREAT R/R FOLLICULAR LYMPHOMA AND DLBCL |
| 11.06 13:51 | dpa-AFX: Regeneron, Sanofi Report FDA Approval Of Kevzara To Treat Active PJIA |
| 11.06 13:04 | dpa-AFX: *REGENERON AND SANOFI: FDA APPROVES KEVZARA FOR TREATMENT OF ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS |
| 04.06 15:31 | dpa-AFX: *FIBROGEN +15% - VEREINBARUNG MIT REGENERON ÜBER KLINISCHE STUDIEN |
| 04.06 13:18 | dpa-AFX: *FIBROGEN VORBÖRSLICH +15% - VEREINBARUNG MIT REGENERON ÜBER KLINISCHE STUDIEN |
| 31.05 08:10 | US-Prüfung für Sanofi-Arznei Dupixent um drei Monate verlängert |
| 31.05 07:29 | dpa-AFX: Sanofi, Regeneron: Dupixent Recommended For EU Approval By CHMP To Treat COPD Patients |
| 31.05 07:19 | dpa-AFX: Regeneron : FDA Extends Review Period For Dupixent As COPD Treatment By Three Month |
| 31.05 07:04 | dpa-AFX: *REGENERON: FDA EXTENDS TARGET ACTION DATE OF SBLA FOR DUPIXENT FOR COPD PATIENTS WITH TYPE 2 INFLAMMATION BY THREE MONTHS |
| 13.05 12:37 | FDA prüft Antrag von Regeneron und Sanofi für Dupixent vorrangig |
| 13.05 07:56 | dpa-AFX: Regeneron : Dupixent SBLA Accepted For FDA Priority Review For Adolescent Chronic Rhinosinusitis |
| 13.05 07:39 | dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS |
| 02.05 13:31 | dpa-AFX: Regeneron Pharmaceuticals Q1 Profit Decreases, misses estimates |
|
|
